Background: In general there is susceptibility for the disease in pediatric age group (12). It has been shown that 2 % of affected individuals are children in certain parts of the world (13). Development of severe disease in children has been linked to comorbidities such as malnutrition, asthma, neuropsychiatric disorders, epilepsy, congenital abnormalities and type 1 diabetes mellitus) (14, 15). In Iraq, reports about clinical presentation and severity of disease in pediatric age group are scanty; therefore. Aim of the study: The aim of the current study was to highlight the main clinical features and clinical severity of COVID-19 in children. Patients and methods: The current cross-sectional research was conducted in Iraq's Al-Diwaniyah Province's Children and Maternity Teaching Hospital. The study included 400 children who tested positive for COVDI-19 using RT-PCR after nasopharyngeal swabs. The study included 220 males and 180 females ranging in age from 1 month to 15 years. The severity of disease was considered according to medication required so that children required no oxygen therapy were regarded as mild cases, children required oxygen therapy were regarded as moderate cases while those requiring mechanical ventilation or Continuous positive airway pressure were considered severe cases.
Background: The proportion of children affected with COVID-19 accounted for approximately 1 to 2 % of all infected cases and the disease often follows a mild to moderate disease. Increased coagulation and events that are thrombotic were repeatedly recorded in adult patients with COVID-19. Nevertheless, till now, there is no consensus about thrombotic events in children in published articles. Aim of the study: to make evaluation of d-dimer level in children with COVID-19 and the rate of thrombotic complications. Patients and methods: The present research that is of cross sectional type was carried out in Children and Maternity Teaching Hospital in Al-Diwaniyah Province, Iraq. The study included 168 children with COVDI-19 proved by positive RT-PCR results following nasopharyngeal swabs. The age ranged from one month up to 15 years and the study included 77 girls and 91 boys. Results: The current study included 168 children affected by COVID-9. The median level of d-dimer in those enrolled children was 0.3 µg/ml with a range of 0.05 to 11 µg/ml. According to a cutoff value of > 0.05 µg/ml, children were categorized into 73 (43.5 %) cases as having high d-dimer level and 95 (56.5 %) as having normal d-dimer level.
Background: The inflammatory reaction that is systemic to the infection with the virus (SARS-CoV-2) stands as the pathognomonic feature of this viral illness, and the majority of hospital admitted patients exhibit unusual biomarkers of inflammation. The protein C-reactive was also connected to severe illness in individuals with pneumonia caused by H1N1 influenza, and several researchers have described a link between COVID-19 disease severity and higher concentration of CRP. Aim of the study: The goal of the current research was to investigate the association among severity of COVID-19 in children, clinical presentation and the concentration of (HS-CRP). Methods and patients: The present research which is of cross sectional kind was practiced in Children and Maternity Teaching Hospital in Al-Diwaniyah Province, Iraq. The study included 200 children with COVDI-19 proved by positive RT-PCR results following nasopharyngeal swabs. The range of the age was from 1 month up to 15 years and the study included 110 males and 90 females. All children were investigated for the level of HS-CRP and the interpretation of levels was based on categorization into normal, moderate elevation, marked elevation and severe elevation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.